Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by H Mukai
Total Records ( 2 ) for H Mukai
  Y Naito , H Mukai and S. Nagai

Previous reports have demonstrated that treatment efficacy is not modified by age and that there are no major differences in outcomes among stage-matched patients as their ages increase. However, there seems to be a substantial undertreatment in the elderly.


We reviewed consecutive patients with breast cancer, 60 years old or older, between July 2003 and March 2007. Patient characteristics, clinicopathologic factors and treatment delivery were retrieved from medical records. Patients were subdivided into two groups (mid-elderly, 60–74 years old and high-elderly, 75 years old or older) and compared based on these factors.


A total of 280 patients were included. All were female. Sixteen percent were high-elderly. Most patients had favorable performance status (0/1, 87%), positive estrogen receptor (57%), negative human epidermal growth factor receptor 2 overexpression (65%) and axillary lymph node metastases (57%). The high-elderly group had significantly less human epidermal growth factor receptor 2 overexpression and less axillary lymph node metastasis. Chemotherapy was administered to 180 patients, and among them, those in the high-elderly group underwent significantly less chemotherapy (P < 0.001). Both anthracycline and taxane were significantly less frequently administered in high-elderly (P < 0.001, respectively). An alternative regimen for anthracycline and taxane was mainly a 5-fluorouracil-based single agent. Chemotherapy was omitted in 12 patients (3 mid-elderly and 9 high-elderly) because of age, and in 9 patients, age was the only reason for omitting chemotherapy.


We confirmed that elderly patients were substantially undertreated. The development of a safer and more efficacious treatment strategy is urgently needed.

  H Mukai , T Takashima , Y Hozumi , T Watanabe , S Murakami , N Masuda , S Mitsuyama , T Ohmura , T Yajima and Y. Ohashi

This randomized controlled trial will compare oral 5-fluorouracil derivatives, TS-1, with intravenous standard chemotherapy such as taxanes in women with metastatic or recurrent breast cancer. Patients with hormone-resistant breast cancer are assigned to either TS-1 (40–60 mg twice daily for 28 consecutive days, followed by a 14-day rest period) or standard chemotherapy (docetaxel 60–75 mg/m2 at 3- or 4-week intervals, paclitaxel 175 mg/m2 at 3- or 4-week intervals or paclitaxel 80–100 mg/m2 weekly, followed by a 1-week rest period). Treatment will be repeated until tumor progression or ≥4 courses for TS-1 and ≥6 courses for taxanes. The primary endpoint is overall survival. Secondary endpoints are progression-free survival, time to treatment failure, adverse events, health-related quality of life and cost-effectiveness. A threshold hazard ratio of 1.333 will be used to determine whether overall survival in the TS-1 group is equivalent (not inferior) to that in the taxane group. The target number of registered patients is 600.

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility